Alcoholic Hepatitis: Diagnosis, Treatment & Prevention
Heavy drinking can trigger inflammatory liver failure that masquerades as sepsis: jaundice, coagulopathy, infection vigilance, prednisolone conversations, transplantation triggers, abstinence plans, ward monitoring.
Featured snippet
Alcoholic hepatitis (AH) is necro-inflammatory liver injury precipitated by heavy ethanol use—it presents with inflammatory cholestasis (jaundice, dark urine, itch), hepatic dysfunction (INR prolongation despite not being “on warfarin”), and sometimes fever or right upper quadrant tenderness that can mimic biliary infection. Severe AH (commonly stratified using Maddrey discriminant function, MELD, or related scores per local pathways) warrants glucocorticoid evaluation when active infection or uncontrolled gastrointestinal bleeding does not forbid it, meticulous infection surveillance, renal monitoring, nutritional rescue, simultaneous alcohol use disorder bridging, possible transplant-center dialogue for steroid-refractory catastrophe.
At a glance: AH is ethanol-driven liver inflammation—not viral—and ward teams differentiate mild from steroid-eligible severe disease using objective scores plus bedside infection and bleeding exclusions.
- Alcoholic hepatitis nests inside the broader alcohol-associated liver disease spectrum—from steatosis to cirrhosis—and overlaps clinically with overlapping metabolic injury such as concurrent NAFLD patterns.
- Severity tools (examples: Maddrey DF, MELD, GAHS variants, Glasgow AH score per hospital policy) quantify candidacy for prednisolone or IV equivalents; clinicians apply day-7 response metrics such as the Lille score to decide early steroid cessation.
- Parallel priorities are culture-negative until proven otherwise, chest source control, fungal awareness in prolonged ICU stays, granular fluid balance guarding against hepatorenal syndrome physiology, thromboprophylaxis decisions set by INR/bleeding phenotype, bowel strategies for hepatic encephalopathy incl. lactulose titration aligned to stool chemistry.
- Psychiatry/addiction liaison plus thiamine supplementation with glucose caution frames safer detox while jaundiced—never discount withdrawal simply because hepatic coma also presents with agitation.
- Teams rehearse escalation when mean arterial pressure drifts despite fluid, ammonia climbs with deepening somnolence, haemoglobin falls without traumatic explanation, or new oxygen requirements herald aspiration—coordinate intensive care, hepatology, interventional bleed management early.
⚡ Quick Facts
💡 Teaching point
Jaundiced “sepsis” without a nailed source? Before reflex broad-spectrum cycles alone expand, juxtapose hepatitis chemistry (AST>ALT but not universally), INR climb, ammonia context, bedside asterixis—for AH can mirror septic shock physiology while sterile. Early hepatology paging prevents both blind steroid abandonment and steroid continuation through occult perforated gut.
📋 Contents
What is alcoholic hepatitis?
Alcoholic hepatitis describes a cytokine-mediated flare within alcohol-associated liver disease in which ethanol metabolites—chiefly acetaldehyde—and gut-derived endotoxins trigger Kupffer cell activation, neutrophilic infiltration of lobules and balloon degeneration of hepatocytes. Clinically this translates into escalating conjugated bilirubin, exaggerated systemic inflammation (tachycardia, fever-ish curve, leukocytosis), and deterioration of hepatic synthesis (falling platelets, INR drift) that can worsen even after drinking stops once the inflammatory avalanche is underway.
Because many patients unknowingly progress through silent fatty change only to surface clinically at the AH stage—or after an intermittent binge atop chronic daily drinking—timing of last drink seldom dissuades hepatology suspicion when corroborative history collateral and laboratory trajectories agree. Repeated flares scaffold bridging fibrosis; therefore each admission is simultaneously an opportunity to redefine drinking goals, micronutrient deficits, cirrhotic complication risks, transplant candidacy, and psychosocial supports.
Scores & severity buckets bedside teams cite
Interpretive scores convert messy chemistry arrays into shorthand for prognosis and therapy triage—they never supersede clinician gestalt regarding infection sovereignty, covert bleeding or candidacy relative to transplantation. Harmonise calculations with hepatology calculators embedded in electronic records because assay units differ among regions.
| Tool | Ingredients (typical) | Operational use |
|---|---|---|
| Maddrey discriminant function (DF) | Bilirubin & prothrombin time prolongation scaled by historical formula variants | Traditionally separates mild from severe strata; DF ≥32 (or MDF equivalent) anchors many corticosteroid pathways—verify exclusions before administration. |
| MELD (+ Na variant) | Bilirubin, INR, creatinine (± sodium adjustment) | Comparable discrimination for transplant listing discussions; ICU teams trend daily when renal axis shifts. |
| ABIC / GAHS lineage | Age, bilirubin, INR, leukocyte count surrogate parameters | Adds granularity where centres favour alternative nomograms alongside Maddrey thresholds. |
| Lille model | Day 0 labs plus day 7 repeats after steroid onset | Discriminates seven-day nonresponse to justify earlier steroid withdrawal if score crosses centre-specific cut-off. |
On a small screen, swipe or scroll sideways to see the full table.
AASLD practice guidance updated in 2019 harmonises much of this landscape but local transplant networks may weight MELD or GAHS differently—always align with the stewardship letter on file for your hospital.
Patterns that should trigger rapid ICU/hepatology co-management include:
- Deepening encephalopathy with rising serum ammonia despite bowel hygiene, or asymmetric pupils suggesting intracranial catastrophe when superimposed on coagulopathy.
- Unexplained gastrointestinal haematemesis or melaena with unstable haemoglobin in a thrombocytopenic coagulopathic host—coordinate endoscopy capacity before assuming variceal versus gastritis source.
- Creatinine climbs >0.3 mg/dL above baseline alongside oliguria refractory to cautious crystalloid—not every hypotensive AH patient tolerates litre boluses absent bleeding control.
- Hypoxaemia outpacing aspiration risk—consider pulmonary infection, ARDS superinfection circuits, hepatic hydrothorax physiology.
Immediate actions: Summon escalation per rapid response/IRL rules, secure airway if Glasgow falls, widen IV access respecting coagulation, send lactate paired with arterial or venous gas via ABG pathways when indicated, marshal blood bank products only per massive transfusion adjunct orders, annotate steroids/antifungals timelines for incoming consultants.
Symptoms
Early AH may masquerade as viral prodrome or toxin exposure—constitutional fatigue, nausea, appetite crash—until bilirubin surfaces on routine chemistry. Established attacks couple cholestasis cues with cytokine fallout: swinging temperature diagrams, tachycardia disproportionate to volume status, proximal muscle wasting from chronic alcohol catabolism.
Typical hepatic storefront signs
- Progressive jaundice, tea urine, generalized pruritus when bile salts itch nerve endings.
- Right upper quadrant discomfort sometimes confused with ascending cholangitis until imaging clarifies bile ducts.
- Easy bruising, gum ooze—falling fibrinogen/platelets plus vitamin K-absorption noise once cholestasis stalls fat-soluble uptake.
- New ascites tightening belts when portal hypertension stealthily matured between flares.
Quietly dangerous variants
- Hepatic encephalopathy camouflaged by alcohol withdrawal tremor—observe handwriting, fixation flutter, arousability after lactulose trial.
- “Septic silhouette” labs without cultured bacteraemia requiring balanced steroids vs antimicrobial overhaul.
- Renal oliguria signalling hepatorenal axis before creatinine visibly jumps—track every void against charted ins/outs.
Ward nurses screen cognitive baselines nightly because ammonia drifts nonlinearly—pair objective West Haven wording with bedside confusion cues rather than sedation scores alone whenever benzodiazepines stay contraindicated.
Causes and Risk Factors
Ethanol dosing patterns
Binge escalation atop daily consumption, drinking on an empty gastric canvas, fortified beverage density, and covert acetaminophen co-ingestion all steepen oxidative stress footprints—yet threshold varies individually; abstinence does not erase already-primed apoptosis overnight.
Women experience fibrosis at lower lifetime ethanol grammes due to gastric first-pass differences, estrogen–cytochrome interplay, body composition partitioning, aligning with wards seeing female AH patients comparatively younger relative to labelled “drink limits.” Nutritional famine (protein starvation, micronutrient voids), iron overload phenotype, adiposity-related inflammation, untreated viral hepatitis C, and mitochondrial genetic vulnerabilities further tailor who inflames.
Co-pathologies that escalate risk
- Superimposed autoimmune hepatitis antibodies occasionally surge after alcohol cessation—coordinate serology timelines so steroids help rather than veil dual pathology.
- Polysubstance ingestion including acute intoxication may delay presentation until airway priorities settle.
- Metabolic overlays with NAFLD/NASH phenotype widen AST/ALT ratio interpretation cautions.
How is it Diagnosed?
Clinical assessment
Collate collateral drinking chronology—not solely self-report after encephalopathy—and inventory every hepatotoxin (acetaminophen, supplements, tuberculosis therapy). Abdominal examination hunts splenomegaly, asterixis, caput, ascites percussion shifts; quantify encephalopathy grade for ICU communication.
Laboratory investigations
- Track liver function tests kinetic curves (bilirubin, transaminases, ALP discordance), CBC for neutrophilia, baseline INR, renal panel for Maddrey/MELD components, ammonia with lab-specific handling quirks.
- Blood cultures, chest imaging, urinary diagnostics per sepsis huddles even when provisional steroids loom—culture-negative bacteraemia intuition still demands source control choreography.
Imaging & confirmatory biopsy role
- Abdominal ultrasound delineates bile duct calibre, infiltrative masses unexpectedly redirecting teamwork toward hepatocellular carcinoma pathways.
- CT reserved for complication mapping (intestinal perforation suspicion, hepatic necrosis topography) respecting contrast–creatinine equipoise.
- Transjugular biopsy arises when steroid commitment hinges on definitively excluding autoimmune overlap—rare routine ward task yet crucial data when serology waffles.
| Biochemical theme | Interpretation checkpoint |
|---|---|
| AST ≫ ALT modestly—neither universally true nor pathognomonic | Pair with INR rise and clinical context vs ischaemic or viral hepatitis. |
| Leukocytosis / left shift | Discriminates inflammatory AH from uncomplicated withdrawal unless infection seeds simultaneously. |
| Creatinine inching upward | Flags hepatorenal syndrome differential—fluid challenges only within prescribed ceilings. |
On a small screen, swipe or scroll sideways to see the full table.
Clinical decision flow
- Step 1 – Stabilise & score: Trend vitals/labs serially rather than trusting admission single-draw; instantiate Maddrey/MELD/GAHS calculators per formulary spreadsheet while infection screens spin.
- Step 2 – Decide steroid eligibility: If severe by agreed threshold and exclusion list clears, prescribe oral prednisolone (often 40 mg daily) or IV glucocorticoid equivalent per protocol—document fungal prophylaxis debates per centre.
- Step 3 – Day 7 Lille choreography: Schedule paired labs enabling Lille/nonresponse adjudication—nurses flag missed draws because timing errors erase interpretability.
- Step 4 – Nutritional bridging: Consult dietetics early; escalate to nasogastric/enteral adjuncts aligning with feeding tube care bundles when voluntarily intake <50% estimated needs.
- Step 5 – Addiction & transplant parallel paths: Pair psychiatry, social work, addiction medicine bedside alongside hepatology—even if transplantation remains distant.
Differential Diagnoses
| Alternative | Discriminating features |
|---|---|
| Acute liver failure | Hyperacute INR/ENCEPH without established cirrhosis history; toxin screens dominate. |
| Ischaemic (“shock”) liver | AST/ALT leaps after hypotensive insult; imaging shows patchy congestion; steroids generally unwarranted. |
| Viral hepatitis A/E flare | IgM serology positivity; epidemiological risk; steroid pathway differs. |
| Cholangitis/obstructive pathology | Dilated ducts on ultrasound, charismatic Charcot triad/REYNOLDS equivalents—often needs ERCP not AH steroids. |
| Heart failure hepatic congestion | Jugular venous hypertension, echocardiography clues, favourable diuresis laboratories. |
On a small screen, swipe or scroll sideways to see the full table.
Overlaps exist—acute-on-chronic liver failure bridges AH with cirrhotic reserve collapse; communication should label trajectory explicitly for transfer teams coordinating acute liver failure escalation thresholds accurately.
Treatment Options
Management layers abstinence scaffolding, anti-inflammatory therapy for selected severe AH, infection control, renal-protective physiology, nutrition, and—for highly selected refractory cases—transplantation timelines. Nothing substitutes for simultaneous treatment of alcohol use disorder alongside organ support.
First-line inpatient measures
- Full alcohol withdrawal prophylaxis per protocol with thiamine before carbohydrate loads; monitor overlap with encephalopathy.
- Diagnose/treat infection vigorously—antibiotics paired with source control beat empiric steroid continuation through occult sepsis.
- Energetic dietetics: high-protein supplementation when encephalopathy allows; enteral routes when volitional intake fails.
Pharmacologic anti-inflammatory therapy
- Oral prednisolone (~40 mg daily) or IV methylprednisolone equivalent for severe AH without contraindications—explicitly document fungal prophylaxis decisions per centre.
- Pentoxifylline monotherapy lost guideline favour across many networks; still note when historical protocols persist locally.
- N-acetylcysteine adjuncts appear in some combination bundles—only per hepatology research protocols or explicit orders.
Transplantation & rescue options
Early liver transplantation for steroid-refractory severe AH exists in experienced programmes with intensive psychosocial vetting; outside those pathways default support emphasises infection control, renal replacement, airway protection, and surrogate consent conversations.
Clinical Practice Considerations
- Monitoring cadence: Chemistry panels at least daily while inflamed; recalculate scores when bilirubin or creatinine shifts >20% day-to-day; document Glasgow coma scale alongside ammonia when encephalopathy fluctuates.
- Drug–drug vigilance: Hold nephrotoxic agents unless mandatory; align NSAID avoidance with bleed/renal risk; annotate proton-pump therapy decisions when variceal vigilance competes with stress-ulcer prophylaxis arguments.
- Adherence & escalation: Reassess steroid response at protocolised day-7 window; define treatment failure as rising MELD despite therapy, new organ support requirements, or uncontrollable infection.
- Referral: Any consideration of transplant listing, TIPS, trial enrolment or interventional haemostasis routes through named hepatology consultants with documented discussion timestamps.
Possible Complications
- Hepatorenal physiology with rising creatinine needing albumin/vasoconstrictor bundles per specialist recipe—not generic fluid flooding.
- Bacterial peritonitis spontaneously or catheter-related when paracentesis pursued—prophylactic antibiotic policies differ for high-risk paracentesis subsets.
- Variceal bleeding when portal hypertension emerges—coordinate endoscopic banding timelines with coagulopathy correction strategy.
- Hepatic encephalopathy grades III–IV predisposing to aspiration—airway ownership discussions early.
- Invasive fungal disease when prolonged steroids/ICU—not every fever is alcoholic inflammation alone.
Prevention
Clinician-facing prevention concentrates on reproducible abstinence metrics, vaccinations where cirrhosis is emerging, micronutrient repletion, and harm-reduction touchpoints—not generic pamphleteering.
- Bundle brief intervention scripts with pharmacotherapy initiation windows (acamprosate, naltrexone, baclofen) per local addiction formulary parity.
- Screen for covert viral coinfection eliminating confounders ahead of blaming alcohol exclusively.
- Weight and glycaemic control when NAFLD coexists lowers second-hit inflammation risk.
Prognosis and Outlook
Mild AH may regress biochemically across weeks-to-months when abstinence holds; severe steroid-treated cohort splits into responders gaining ~two-month mortality advantage versus refractory subsets still facing double-digit inpatient death risks. Repeated admissions erode hepatic reserve and psychosocial capital—six-month hepatology follow-up with documented drinking biomarkers predicts late survival better than discharge bilirubin alone.
In clinical practice…
- Name the steroids aloud during handoff—“40 prednisolone day 4 of 28 unless Lille dictates stop”—prevents phantom continuation after transfers.
- Pair nursing neuro checks with bedside glucose dips when poor oral intake clashes with insulin orders from overlapping diabetes teams.
- Document last drink timelines adjacent to symptom onset for future legal-consent clarity around transplantation candidacy narratives.
Bedside monitoring checklist
- Neurology tier: arousability, asterixis, limb tone, seizure precautions when electrolytes yo-yo.
- Perfusions: lactate clears, stool output vs lactulose goal, vasopressor weaning maps.
- Renal/Oliguria trackers against albumin-containing protocols when hepatorenal syndrome suspected.
- Glucose swings, phosphate repletion deficits, GI bleed trace (coffee-ground NG, stool colour).
- Infection cues: spikes after line draws, cellulitis gateways, aspiration lung exam after encephalopathy shifts.
When to Seek Emergency Care
- Combative decline in consciousness with diminishing cough reflex while jaundiced—activate emergency airway pathway.
- Haemodynamic collapse with INR >2.5 unexplained by anticoagulant charting.
- Hematemesis exceeding cupful increments or brisk melaena with postural dizziness.
- Creatinine doubling within 72 h amid oliguria refractory to protocolised albumin boluses ordered by hepatology.
Outside hospital, escalating acutely jaundiced patients with confusion or hemorrhage parallels emergency seizure for community nursing hotlines—coordinate ambulance activation per regional policy rather than clinician self-transport speculation.
Deterioration & escalation
- Spiking oxygen requirements when hepatopulmonary shunt physiology overlaps pneumonia.
- New atrial fibrillation with rapid ventricular rates suggesting sepsis, alcohol withdrawal tachycardia—or both.
- Platelet declines >15% sequentially without heparin exposure—think splenic entrapment plus consumptive physiology.
- Summon ICU when vasopressor dependency appears, ammonia refractory to escalating bowel regimen, bedside ultrasound shows significant ascites jeopardising diaphragmatic mechanics.
- Notify interventional gastroenterology for refractory bleed; notify transplant registrar when MELD >32 pattern emerges with steroid failure—local threshold dependent.
Nursing management
Acute stabilization
- Cluster labs to conserve veins yet never skip timed Lille draws accidentally.
- Coordinate glucose checks with CIWA overlaps—benzodiazepine stacking risks respiratory depression when ammonia already climbing.
Nutrition & lines
- Hourly aspiration precautions on NG feeds when gag reflex doubtful.
- Daily sedation vacation plans only when ICU protocols permit—coordinate with ammonia trends.
Education & evaluation
- Use teach-back for abstinence contract steps: who to ring when yellow eyes return, when to bypass GP for hepatology voicemail.
- Evaluate shift success by objective deltas: lactulose dosing producing two soft stools, net negative fluid balances agreed with hepatology—not solely “patient comfortable.”
NCLEX practice questions
These NCLEX-style clinical judgment practice items focus on the nursing priorities for this condition — recognise cues, escalate red flags, take safe action and evaluate outcomes (NCSBN Clinical Judgment Measurement Model) — through Priority FIRST, SATA, deterioration trends, multi-patient triage, ordered response, matrix matching and cloze drops on the topic of severe alcoholic hepatitis recognition (Maddrey discriminant function ≥32, MELD severity), structured infection workup, prednisolone with Lille-score reassessment and abstinence-anchored long-term care.
Unfolding case (Questions 1–3): Mr. K., 47, with chronic heavy alcohol use, presents with 4 weeks of jaundice, ascites, anorexia and recent encephalopathy. Bilirubin 220 µmol/L, INR 2.3, AST 180, ALT 90 (AST:ALT 2:1), albumin 22, creatinine 110, MDF 48, MELD 25. Cultures, ascitic-fluid analysis and viral hepatitis screening have been sent. He stopped drinking 5 days ago and is now febrile with a productive cough.
Answer key & rationale
Which Maddrey discriminant function cutoff usually separates mild from severe alcoholic hepatitis in many protocols?
A Maddrey DF of 32 or higher commonly defines severe AH where glucocorticoids are considered if infection, gastrointestinal bleeding and other exclusions are absent—confirm with hepatology calculators used locally.
When should teams calculate the Lille score?
Typically after roughly seven days of corticosteroids to classify response and refine whether to stop therapy early versus continue.
Does normal ammonia exclude hepatic encephalopathy?
No—exam and trends matter; ammonia is supportive but unreliable as a solitary rule-in or rule-out marker.
Why document alcohol withdrawal scores alongside hepatic labs?
Patients may still detox while jaundiced; withdrawal peaks can obscure encephalopathy or precipitate aspiration without structured monitoring.
What renal trajectory should trigger rapid senior review?
Creatinine edging upward with oliguria, especially beside rising bilirubin and hypotension treated with vasopressors—think hepatorenal physiology and align fluid plans with ICU/hepatology.
Which infection concerns most often pause steroids temporarily?
Untreated sepsis, pneumonia, perforated sources, untreated cellulitis, and active major variceal bleeding generally require holding glucocorticoids until sources are stabilised collaboratively.
How does abstinence impact medium-term survival after hospital discharge?
Continuing alcohol use after an AH admission carries very high relapse mortality; timely addiction medicine linkage meaningfully bends survival curves versus medical therapy alone.
When might transplant teams evaluate catastrophic AH despite short abstinence intervals?
Selected tertiary programmes discuss early transplantation for steroid-refractory severe AH following rigorous psychosocial assessment—outside that pathway default is optimisation, infection control, nutritional rescue and intensive care escalation.
- American Association for the Study of Liver Diseases (AASLD). Alcohol-associated liver disease (practice guidance hub, updated July 2019).aasld.org/practice-guidelines/alcohol-associated-liver-disease
- Shah NJ, Royer A, John S. Alcoholic-associated hepatitis. StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2026 (NCBI Bookshelf).ncbi.nlm.nih.gov/books/NBK470217
- National Institute for Health and Care Excellence (NICE). Alcohol-use disorders: diagnosis and management of physical complications. Clinical guideline CG100.nice.org.uk/guidance/cg100
- National Institute for Health and Care Excellence (NICE). Alcohol-use disorders: diagnosis, assessment and management of harmful drinking and alcohol dependence. Clinical guideline CG115.nice.org.uk/guidance/cg115
- National Institute for Health and Care Excellence (NICE). Alcohol-use disorders: diagnosis and management quality standard QS11.nice.org.uk/guidance/qs11
- National Health Service (NHS). Alcohol-related liver disease overview (ARLD).nhs.uk/conditions/alcohol-related-liver-disease-arld
- World Health Organization (WHO). Alcohol fact sheet.who.int/news-room/fact-sheets/detail/alcohol
- Centers for Disease Control and Prevention (CDC). Alcohol use and your health (US population-health context).cdc.gov/alcohol/about-alcohol-use/index.html
- National Institute on Alcohol Abuse and Alcoholism (NIAAA), NIH. Understanding alcohol use disorder (AUD assessment & treatment overview).niaaa.nih.gov/publications/brochures-and-fact-sheets/understanding-alcohol-use-disorder
- American Liver Foundation. Alcohol-associated liver disease (patient-oriented overview aligned with clinician teaching points).liverfoundation.org/for-patients/alcohol-related-liver-disease